Skip to main content

ACR 2022 Tweet by Mike Putman

View on
Interested in this late-breaker, comparative study of secukinumab (IL17) vs adalimumab (TNF) in AxSpa

No difference in radiographic progression at 1 year - in line with my perception of relative equality for these treatments

Need long term data!

#ACR22 @rheumnow abstr#L15
Image from Mike Putman’s tweet
×